Valuation: Genome & Company

Market Cap 24TCr 17Cr 15Cr 14Cr 13Cr 24Cr 1.63TCr 24Cr 162.55Cr 64Cr 818.51Cr 64Cr 63Cr 2.72TCr P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 22TCr 16Cr 14Cr 13Cr 12Cr 22Cr 1.51TCr 22Cr 150.54Cr 59Cr 758Cr 59Cr 58Cr 2.52TCr EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
85.14%
Yield 2024 *
-
Yield 2025 -
13/04 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
03/04 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
13/03 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
22/25/22 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
21/25/21 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
11/25/11 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
28/25/28 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
24/25/24 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
24/25/24 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
24/25/24 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
19/24/19 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
17/24/17 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24/24/24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day+3.59%
1 week+28.33%
Current month+40.85%
1 month+17.41%
3 months-33.04%
6 months-41.15%
Current year-32.85%
1 week 3,675
Extreme 3675
4,720
1 month 2,975
Extreme 2975
4,720
Current year 2,975
Extreme 2975
10,180
1 year 2,440
Extreme 2440
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
28,800
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 24/09/2015
Chief Executive Officer 55 24/09/2015
Director TitleAgeSince
Director/Board Member 55 24/09/2015
Director/Board Member 62 -
Director/Board Member 63 28/03/2025
Date Insider Type Main position Quantity % Market Cap.
09/05/25 Don

Chief Executive Officer

1,00,000 0.3217%
09/05/25 Free

Director

40,000 0.1287%
09/05/25 Free

Public Communications Manager

50,000 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
+3.59%+28.33%+70.79%-39.13% 16Cr
-1.78%-1.68%+1.99%+13.84% 4.92TCr
+0.13%-1.75%+459.59%+571.88% 4.33TCr
-2.77%-0.65%+11.73%+69.50% 4.05TCr
-1.85%-0.51%+25.39%+7.89% 3.98TCr
-0.50%+3.08%+19.91%+47.26% 3.27TCr
+0.38%-3.56% - - 1.62TCr
-0.65%-1.77%+26.50%+118.43% 1.62TCr
+0.49%+0.92%+4.32%+22.16% 1.4TCr
-1.45%+3.70%+78.04%+27.89% 1.34TCr
Average -0.46%+3.04%+77.59%+93.30% 2.66TCr
Weighted average by Cap. -1.17%+2.55%+94.99%+131.23%

Financials

2024 2025
Net sales 2.77TCr 1.96Cr 1.7Cr 1.59Cr 1.45Cr 2.72Cr 187.68Cr 2.77Cr 19Cr 7.3Cr 94Cr 7.37Cr 7.21Cr 312.33Cr 2.46TCr 1.74Cr 1.5Cr 1.41Cr 1.28Cr 2.41Cr 166.32Cr 2.45Cr 17Cr 6.47Cr 83Cr 6.53Cr 6.39Cr 276.78Cr
Net income -2.01TCr -1.42Cr -1.23Cr -1.15Cr -1.05Cr -1.97Cr -136.05Cr -2.01Cr -14Cr -5.29Cr -68Cr -5.34Cr -5.23Cr -226.41Cr -642.81Cr -45.47L -39.28L -36.91L -33.57L -63.11L -43Cr -64.15L -4.32Cr -1.69Cr -22Cr -1.71Cr -1.67Cr -72Cr
Net Debt -4.89TCr -3.46Cr -2.99Cr -2.81Cr -2.55Cr -4.8Cr -330.84Cr -4.88Cr -33Cr -13Cr -165.67Cr -13Cr -13Cr -550.55Cr -1.79TCr -1.26Cr -1.09Cr -1.03Cr -93.27L -1.75Cr -120.83Cr -1.78Cr -12Cr -4.7Cr -61Cr -4.74Cr -4.64Cr -201.08Cr
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
14/26/14 4,620.00 +3.59% 3,33,422
13/26/13 ₩4,460.00 +0.68% 2,87,276
12/26/12 ₩4,430.00 +5.73% 4,26,447
11/26/11 ₩4,190.00 +0.72% 5,56,965
10/26/10 ₩4,160.00 +14.60% 22,82,622
  1. Stock Market
  2. Stocks
  3. A314130 Stock